Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report

B cell maturation antigen (BCMA)-directed CAR-T cell therapy is a disruptive approach for treating relapsed/refractory multiple myeloma (R/R MM); however, optimization is necessary to maximize patient benefit. We report the case of a 61-year-old woman with primary refractory MM who presented with hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dan, Que, Yimei, Ding, Shengnan, Hu, Guang, Wang, Wen, Mao, Xia, Wang, Ying, Li, Chunrui, Huang, Liang, Zhou, Jianfeng, Zhang, Wei, Xiao, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511648/
https://www.ncbi.nlm.nih.gov/pubmed/36137648
http://dx.doi.org/10.1136/jitc-2022-005403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511648/
https://www.ncbi.nlm.nih.gov/pubmed/36137648
http://dx.doi.org/10.1136/jitc-2022-005403

Ejemplares similares